Solid Biosciences
A US life science company focused on advancing a portfolio of neuromuscular and cardiac programs.
The company's portfolio includes SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne, AVB-202, a gene transfer candidate for the treatment of Friedreich’s Ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases.
The neuromuscular and cardiac diseases specialist announced a strategic collaboration with Phlox in January 2023 to target a severe form of genetic dilated cardiomyopathy for which there is currently a significant unmet need for effective treatments.
Latest Solid Biosciences News & Features
12 January 2023
3 October 2022
23 October 2020
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze